Assessment of Efficacy, Safety and Tolerability of Fixed Dose Combination Wunder Eye Cream (3% Biophytex LS 8740 an 5% Proteasyl TP LS 8657) in the treatment of under Eye Dark Circles. - NI

Glenmark Pharmaceuticals Limited0 个研究点目标入组 20 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•?Subjects with mild, moderate or severe under eye dark circles
•?Subjects must be 18-50 years of age
•?Both males and females
•?Subjects with no history of glaucoma, any eye infection and with normal range of intraocular pressure
•?Subjects must provide written informed consent and comply to the protocol
•?Wash out period of 14 or more days prior to enrollment in case of subjects using any other skin care products.

•?Subjects not willing to discontinue all topical treatments for ?Under Eye? dark circles for 2 weeks prior to enrollment in study
•?Hypersensitivity to any ingredients of Wunder Eye cream
•?Pregnant and lactating women
•?Subjects taking Concomitant therapy that might interfere with the study results
•?Subjects with dermatological disorder of face that may interfere with study evaluation
•?Subjects who have undergone any surgical treatment of the face
•?Subjects with abnormal intraocular pressure, history of glaucoma and any eye infection on ophthalmological examination
•?Concomitant topical therapy in under eye area that causes hypopigmentation includes Retinoids and Hydroquinone skin peels.
•?Concomitant medicines, that cause hyper pigmentation, include Phenothiazines, Anti-malarials (Chloroquine), Phenytoin sodium, cytotoxic drugs, Sulphonamides.

发起方